Terms: = Breast cancer AND TOP2A, TOP2, TP2A AND Clinical Outcome
14 results:
1. top2a Expression in Pheochromocytoma and Abdominal Paraganglioma: a Marker of Poor clinical outcome?
Solhusløkk Höse K; Stenman A; Svahn F; Larsson C; Juhlin CC
Endocr Pathol; 2023 Mar; 34(1):129-141. PubMed ID: 36656469
[TBL] [Abstract] [Full Text] [Related]
2. Identification of potential key genes for HER-2 positive breast cancer based on bioinformatics analysis.
Lin Y; Fu F; Lv J; Wang M; Li Y; Zhang J; Wang C
Medicine (Baltimore); 2020 Jan; 99(1):e18445. PubMed ID: 31895772
[TBL] [Abstract] [Full Text] [Related]
3. Functional transcriptomic annotation and protein-protein interaction network analysis identify NEK2, BIRC5, and top2a as potential targets in obese patients with luminal A breast cancer.
Nuncia-Cantarero M; Martinez-Canales S; Andrés-Pretel F; Santpere G; Ocaña A; Galan-Moya EM
Breast Cancer Res Treat; 2018 Apr; 168(3):613-623. PubMed ID: 29330624
[TBL] [Abstract] [Full Text] [Related]
4. RRM1, TUBB3, top2a, CYP19A1, CYP2D6: Difference between mRNA and protein expression in predicting prognosis of breast cancer patients.
Xu YC; Zhang FC; Li JJ; Dai JQ; Liu Q; Tang L; Ma Y; Xu Q; Lin XL; Fan HB; Wang HX
Oncol Rep; 2015 Oct; 34(4):1883-94. PubMed ID: 26252353
[TBL] [Abstract] [Full Text] [Related]
5. Allelic imbalance at the HER2/top2a locus in breast cancer.
Huijsmans CJ; van den Brule AJ; Rigter H; Poodt J; van der Linden JC; Savelkoul PH; Hilbink M; Hermans MH
Diagn Pathol; 2015 May; 10():56. PubMed ID: 26022247
[TBL] [Abstract] [Full Text] [Related]
6. HER2 and top2a amplification in a hospital-based cohort of breast cancer patients: associations with patient and tumor characteristics.
Fasching PA; Weihbrecht S; Haeberle L; Gasparyan A; Villalobos IE; Ma Y; Ekici AB; Wachter DL; Hartmann A; Beckmann MW; Slamon DJ; Press MF
Breast Cancer Res Treat; 2014 May; 145(1):193-203. PubMed ID: 24682655
[TBL] [Abstract] [Full Text] [Related]
7. DNA repair gene patterns as prognostic and predictive factors in molecular breast cancer subtypes.
Santarpia L; Iwamoto T; Di Leo A; Hayashi N; Bottai G; Stampfer M; André F; Turner NC; Symmans WF; Hortobágyi GN; Pusztai L; Bianchini G
Oncologist; 2013; 18(10):1063-73. PubMed ID: 24072219
[TBL] [Abstract] [Full Text] [Related]
8. Prognostic impact of polymorphisms in the MYBL2 interacting genes in breast cancer.
Shi H; Bevier M; Johansson R; Enquist-Olsson K; Henriksson R; Hemminki K; Lenner P; Försti A
Breast Cancer Res Treat; 2012 Feb; 131(3):1039-47. PubMed ID: 22037783
[TBL] [Abstract] [Full Text] [Related]
9. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients.
Györffy B; Lanczky A; Eklund AC; Denkert C; Budczies J; Li Q; Szallasi Z
Breast Cancer Res Treat; 2010 Oct; 123(3):725-31. PubMed ID: 20020197
[TBL] [Abstract] [Full Text] [Related]
10. Topoisomerase II alpha gene copy loss has adverse prognostic significance in ERBB2-amplified breast cancer: a retrospective study of paraffin-embedded tumor specimens and medical charts.
Usha L; Tabesh B; Morrison LE; Rao RD; Jacobson K; Zhu A; Basu S; Coon JS
J Hematol Oncol; 2008 Aug; 1():12. PubMed ID: 18702822
[TBL] [Abstract] [Full Text] [Related]
11. Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients.
Tan DS; Marchió C; Jones RL; Savage K; Smith IE; Dowsett M; Reis-Filho JS
Breast Cancer Res Treat; 2008 Sep; 111(1):27-44. PubMed ID: 17922188
[TBL] [Abstract] [Full Text] [Related]
12. HER2, top2a, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer.
Al-Kuraya K; Novotny H; Bavi P; Siraj AK; Uddin S; Ezzat A; Sanea NA; Al-Dayel F; Al-Mana H; Sheikh SS; Mirlacher M; Tapia C; Simon R; Sauter G; Terracciano L; Tornillo L
J Clin Pathol; 2007 Jul; 60(7):768-72. PubMed ID: 16882699
[TBL] [Abstract] [Full Text] [Related]
13. Topoisomerase II-alpha gene deletion is not frequent as its amplification in breast cancer.
Park K; Han S; Gwak GH; Kim HJ; Kim J; Kim KM
Breast Cancer Res Treat; 2006 Aug; 98(3):337-42. PubMed ID: 16502015
[TBL] [Abstract] [Full Text] [Related]
14. HER-2 and top2a coamplification in urinary bladder cancer.
Simon R; Atefy R; Wagner U; Forster T; Fijan A; Bruderer J; Wilber K; Mihatsch MJ; Gasser T; Sauter G
Int J Cancer; 2003 Dec; 107(5):764-72. PubMed ID: 14566826
[TBL] [Abstract] [Full Text] [Related]
